These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18953106)

  • 1. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies.
    Zilka N; Kontsekova E; Novak M
    J Alzheimers Dis; 2008 Oct; 15(2):169-79. PubMed ID: 18953106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy.
    Kontsekova E; Ivanovova N; Handzusova M; Novak M
    Cell Mol Neurobiol; 2009 Sep; 29(6-7):793-8. PubMed ID: 19214739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
    Kanemaru K
    Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
    Sigurdsson EM
    J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Tau immunotherapy: Hopes and hindrances".
    Shahpasand K; Sepehri Shamloo A; Nabavi SM; Ping Lu K; Zhen Zhou X
    Hum Vaccin Immunother; 2018 Feb; 14(2):277-284. PubMed ID: 29049003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau immunotherapy for Alzheimer's disease.
    Pedersen JT; Sigurdsson EM
    Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.
    Gerson JE; Castillo-Carranza DL; Kayed R
    ACS Chem Neurosci; 2014 Sep; 5(9):752-69. PubMed ID: 25075869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.
    Kovacech B; Novak M
    Curr Alzheimer Res; 2010 Dec; 7(8):708-16. PubMed ID: 20678071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Features about Tau Function and Dysfunction.
    Medina M; Hernández F; Avila J
    Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27104579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
    Kayed R; Jackson GR
    Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein truncation as a common denominator of human neurodegenerative foldopathies.
    Jadhav S; Zilka N; Novak M
    Mol Neurobiol; 2013 Dec; 48(3):516-32. PubMed ID: 23516100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Approaches Targeting Pathological Tau Aggregates.
    Gerson J; Kayed R
    Curr Pharm Des; 2016; 22(26):4028-39. PubMed ID: 27189598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.
    Valera E; Spencer B; Masliah E
    Neurotherapeutics; 2016 Jan; 13(1):179-89. PubMed ID: 26494242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
    Kayed R
    Hum Vaccin; 2010 Nov; 6(11):931-5. PubMed ID: 20980799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways.
    Zilka N; Kazmerova Z; Jadhav S; Neradil P; Madari A; Obetkova D; Bugos O; Novak M
    J Neuroinflammation; 2012 Mar; 9():47. PubMed ID: 22397366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in tau-based therapeutics for neurodegenerative diseases.
    Medina M
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):20-30. PubMed ID: 21118095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.